Nuvalent
of met all desired clinical characteristics phase favorable tolerability was observed in preliminary profile presented patients enrolled across six dose levels as may was not reached no clinically significant exposure response relationships for safety and efficacy were observed wide therapeutic window was consistent with selective sparing design the dose level daily maintained steady state plasma levels above target efficacy thresholds i a a i i a i a a a a go me nes me yes target target wild type target periphery target wild type periphery data as for patients treated by data for cohort are not shown due to immaturity centra based hours once daily standard deviation on in in models and respectively values for a and divided by predicted human brain to plasma ratio respectively on file a source | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
April 2024
Slide
36 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
of met all desired clinical characteristics phase selection as was based on the following preliminary profile presented considerations maintained steady state plasma levels at or above the target efficacy thresholds alk wild type and alk single and compound mutations in both the periphery and in the at steady state day key favorable tolerability suggested the potential for a highly alk selective sparing safety profile early anti tumor activity observed in alk positive patients across a wide dose range including at with objective responses observed in as heavily treated patients including those previously treated with one or more second generation is or plus and those who were naive patients with alk single and compound resistance mutations and are not shown due to immaturity predicted efficacy thresholds alk single mutation alk compound mutations alk naive alk single mutation patients with metastases predicted source lin in in models bearing hip alk divided by alk respectively targets for exceed corresponding periphery values | Nuvalent
Investor Presentation
February 2024
of met all desired clinical characteristics phase favorable tolerability was observed in preliminary profile presented patients enrolled across six dose levels as may was not reached no clinically significant exposure response relationships for safety and efficacy were observed wide therapeutic window was consistent with selective sparing design the dose level daily maintained steady state plasma levels above target efficacy thresholds i a a a a a a target target wild type target periphery target wild type periphery data as for patients treated by data for cohort are not shown due to immaturity central nervous system standard deviation hours once daily in models in and respectively based on tumor reg on source data on file a i values for a and divided by predicted human brain to plasma ratio respectively | Nuvalent
Investor Presentation
February 2024
of met all desired clinical characteristics phase selection as was based on the following preliminary profile presented considerations maintained steady state plasma levels at or above the target efficacy thresholds alk wild type and alk single and compound mutations in both the periphery and in the at steady state day key favorable tolerability suggested the potential for a highly alk selective sparing safety profile early anti tumor activity observed in alk positive patients across a wide dose range including at with objective responses observed in a i a heavily treated patients including those previously treated with one or more second generation or plus and those who were naive a patients with alk single and compound resistance mutations and are not shown due to predicted efficacy thresholds alk single mutation alk compound mutations alk naive alk single mutation patients with metastases in in models bearing hip alk divided by a alk respectively a ratio targets for exceed corresponding periphery values | Nuvalent
Investor Presentation
January 2024
of met all desired clinical characteristics phase favorable tolerability was observed in preliminary profile presented patients enrolled across six dose levels as may was not reached no clinically significant exposure response relationships for safety and efficacy were observed wide therapeutic window was consistent with selective sparing design the dose level daily maintained steady state plasma levels above target efficacy thresholds i a a a a a a target target wild type target periphery target wild type periphery data as for patients treated by data for cohort are not shown due to immaturity central nervous system hours once daily standard deviation based on tumor regression in in models bearing and respectively values for a and divided by predicted human brain to plasma ratio respectively source data on file a i | Nuvalent
Related slides by other companies
AstraZeneca
Investor Event
September 2024
promising efficacy in heavily treated patients with ovarian breast and endometrial cancer sie | AstraZeneca
NeuroSense Therapeutics
Investor Presentation
October 2024
modulated and levels showing target engagement | NeuroSense Therapeutics
Kymera
Results
December 2022
degradation profile of and in consistent with preclinical models in blood and tumor bent | Kymera
Alkermes
Investor Day
March 2021
improved synaptic efficacy in wild type mice and restored synaptic function in disease model functional long term potentiation in wild type mice long term potentiation in mice with hippocampal synaptic deficit vehicle in wild type model vehicle in model in model vehicle ordinary one way holm post vehicle in vehicle in in alkermes data on file field excitatory postsynaptic potential wild type mouse model five disease linked mutations in month old mice a so bursts go | Alkermes
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights